Argireline vs TB4-Frag

Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects

Argireline (Acetyl Hexapeptide-3) is a synthetic hexapeptide applied topically in cosmetic formulations to reduce the appearance of expression lines. It is proposed to partially inhibit the SNAP-25 component of the SNARE protein complex, attenuating the strength of muscle contractions that drive dynamic wrinkle formation. Controlled human trials have demonstrated statistically significant reductions in wrinkle depth with repeated topical application compared to placebo, representing some of the stronger human evidence available for a cosmetic peptide. Argireline is classified as a cosmetic ingredient, not a drug; it has not been evaluated by the FDA for efficacy and existing evidence is limited to cosmetic endpoints in small-to-medium trials. Argireline concentration and use: in published cosmetic studies, argireline is used at concentrations of 5–10% in topical formulations, applied to areas of dynamic expression lines such as forehead and periorbital regions. The mechanism of action — partial SNARE complex inhibition rather than complete neurotoxin-class blockade — means the effect is typically described as softening expression line depth rather than eliminating muscle movement. Results in human studies develop over 4–8 weeks of twice-daily application. Argireline vs SNAP-8: SNAP-8 (Acetyl Octapeptide-3) is a longer structural derivative of argireline developed to extend SNARE complex competitive inhibition further along the docking sequence, with manufacturer-sponsored data suggesting improved potency at lower concentrations. The key difference in evidence quality: argireline has independent peer-reviewed human trial data, while SNAP-8 data originates primarily from manufacturer-sponsored studies not indexed in standard biomedical literature. Both are topical cosmetic ingredients and neither carries regulatory drug approval. For cosmetic peptides with more systemic research profiles — including GHK-Cu, which has several decades of independent research — the PeptideBase skin and joint peptides directory covers the broader landscape.

Active fragment of Thymosin Beta-4; promotes actin dynamics and cell migration; activates hair follicle stem cells; modulates inflammatory signaling

TB-4 Fragment (Thymosin Beta-4 17-23) is a short synthetic peptide derived from the thymosin beta-4 protein, investigated for wound healing, skin repair, and hair follicle regeneration. Thymosin beta-4 facilitates actin sequestration, keratinocyte migration, and stem cell recruitment to sites of tissue injury; the 17-23 fragment retains portions of these bioactive properties. Peer-reviewed studies demonstrate that thymosin beta-4 promotes hair follicle stem cell activation and dermal tissue regeneration in preclinical models, providing a mechanistic basis for skin-related applications. TB-4 Fragment is an investigational peptide with limited human clinical data and is not approved by the FDA for any therapeutic use. TB4-Frag vs full-length thymosin beta-4 TB-4 Fragment (residues 17–23 of thymosin beta-4, sequence: Leu-Lys-Lys-Thr-Glu-Thr-Gln) is a distinct, smaller molecule compared to full-length thymosin beta-4 (43 amino acids). The fragment retains the actin-binding motif that drives keratinocyte migration and stem cell recruitment — mechanisms central to the wound healing and hair follicle regeneration research attributed to TB4 — but lacks the full protein's Ac-SDKP-generating and anti-fibrotic properties. The lower molecular weight of the fragment (approximately 870 Da vs ~4,900 Da for full Tb4) is proposed to improve transdermal penetration for topical applications, making TB4-Frag relevant to cosmetic skin and scalp formulations where injectable administration is not used. In the research peptide market, TB4-Frag is positioned as a topical active for skin repair and hair density contexts; full-length thymosin beta-4 (sold as TB-500) is used for systemic/injectable recovery and tissue repair applications. The two should not be conflated — they have different sequences, molecular weights, and proposed application contexts despite sharing a mechanistic origin.